This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): GLPG0634
Description: GLPG0634 is an orally-available inhibitor of JAK1 (Janus kinase 1).
GlaxoSmithKline and Galapagos
In June 2006, GSK and Galapagos initiated an arthritis alliance to discover and develop disease-modifying drugs for GSK's global R&D organization.
The aim of this agreement is for Galapagos to expand its portfolio of novel validated targets in the field of osteoarthritis, to conduct compound screening, identify tractable hits, pursue a number of hit-to-lead programmes, and develop the resulting leads into candidate selection compounds through to a successful Proof of Concept in clinical research Phase IIa. GSK will have exclusive options to further develop and commercialise these compounds on a worldwide basis. Galapagos will have the right to further develop and commercialise compounds for which GSK does not exercise its option.
Under the terms of the agreement, Galapagos will receive an upfront technology access fee of EUR 4 million from GSK. Upon successful completion of all agreed alliance programme criteria, Galapagos stands to...See full deal structure in Biomedtracker
Partners: Galapagos NV
Additional information available to subscribers only: